Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:PRFX

PainReform Q2 2026 Earnings Report

PainReform logo
$0.95 0.00 (0.00%)
Closing price 10/1/2026 03:59 PM Eastern
Extended Trading
$0.97 +0.02 (+1.76%)
As of 10/1/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

PainReform EPS Results

Actual EPS
-$1.13
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PainReform Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PainReform Announcement Details

Quarter
Q2 2026
Date
9/3/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

PainReform Earnings Headlines

PRF Technologies' GridFeed(TM) to Explore Strategic Growth Opportunity in AI Data Center Power Optimization
September 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/16/3363238/0/en/prf-technologies-gridfeed-tm-to-explore-strategic-growth-opportunity-in-ai-data-center-power-optimization.html
PRF Technologies to Establish GridFeed™ as a Standalone Subsidiary to Pursue Strategic Alliances for Its AI-Driven Renewable Energy Trading Platform
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3358645/0/en/prf-technologies-to-establish-gridfeed-as-a-standalone-subsidiary-to-pursue-strategic-alliances-for-its-ai-driven-renewable-energy-trading-platform.html
The only 5 stocks that matter
SpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO as soon as this fall. TradeSmith CEO Keith Kaplan says chasing the next hot IPO isn't necessary. His AI-driven system, built on a platform pioneered by Google, ranks every stock in the S&P 500 and narrows the list to just five names to hold each month. Backtests show the Top Five Stocks outperformed the S&P 500 by 4x in August alone.tc pixel
 |  TradeSmith (Ad)
PRF Technologies Provides First Half 2026 Business Update Highlighting Significant Progress Across Healthcare and AI Energy Business
September 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3355915/0/en/prf-technologies-provides-first-half-2026-business-update-highlighting-significant-progress-across-healthcare-and-ai-energy-business.html
PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms
July 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/27/3333512/0/en/prf-technologies-issues-letter-to-shareholders-highlighting-strengthened-financial-position-and-building-momentum-across-its-biotechnology-and-ai-driven-energy-platforms.html
PRF Technologies to Showcase GridFeed™ at Energy Trading Week Europe 2026
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330457/0/en/prf-technologies-to-showcase-gridfeed-at-energy-trading-week-europe-2026.html
See More PainReform Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PainReform? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PainReform and other key companies, straight to your email.

About PainReform

PainReform (NASDAQ:PRFX) (NASDAQ: PRFX) is a clinical-stage specialty pharmaceutical company focused on developing therapies for the management of acute postoperative pain. The company’s approach is designed to provide prolonged local pain relief while potentially reducing reliance on opioid medications after surgery.

PainReform’s lead product candidate, PRF-110, is an investigational extended-release formulation of ropivacaine, a local anesthetic. The product is designed to be administered at the surgical site and gradually release the anesthetic over an extended period, with the goal of providing sustained pain control during the early recovery period following surgery.

Founded in Israel, PainReform has pursued the clinical development of its product candidates for potential use in postoperative pain management markets, including the United States and other international markets. PRF-110 remains subject to clinical evaluation and regulatory review, and its availability and commercial use depend on receiving applicable approvals.

View PainReform Profile
Earnings Tools